Skip to content

Protection Against Insulin Resistance in Obesity

Protection Against Insulin Resistance in Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02717832
Acronym
PAIR
Enrollment
26
Registered
2016-03-24
Start date
2016-03-31
Completion date
2019-08-09
Last updated
2022-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Obesity

Brief summary

The overall goal of this project is to identify factors that protect some obese adults from becoming insulin resistant. Identifying mechanisms that help protect some obese adults from developing insulin resistance could lead to novel, targeted therapeutic and/or preventative strategies for obese adults who are insulin resistant.

Detailed description

SCREENING PROCEDURES Participants will undergo a battery of initial screening tests including: a detailed health history and physical examination, a physical activity questionnaire, and a body composition assessment. All women will undergo a urine pregnancy test. GENERAL STUDY DESIGN To avoid potential confounding hormonal effects, all women will be studied in the early follicular phase of their menstrual cycle. Subjects will be advised of what they should be eating in the 3 days leading up to their hospital visit to maintain their weight. Subjects will also complete a three day food journal before their hospital visit. The day prior to the study trial admission, subjects will need to eat pre-prepared standardized meals for breakfast, lunch, dinner and an evening snack that the study team has given them. Subjects will be admitted to the Michigan Clinical Research Unit (MCRU) in the morning after a 12-hour, overnight fast. After arrival, subjects will rest quietly in their room for about 30 minutes. The study team will then measure subjects resting metabolic rate for about 20 minutes. After this test, an intravenous (IV) catheter will be placed for infusions and a second IV will be placed in vein of the opposite arm for blood sampling. After the IV placement, the study team will begin a tracer-labeled glucose, or sugar, infusion. The study team will then remove a small sample of muscle from the subjects thigh. This muscle biopsy procedure involves numbing a nickel-sized portion of the skin of the thigh with a local anesthetic, making a small incision (1/4 inch), and removing a small piece of muscle (approximately the size of 2-3 grains of rice). The incision will then be closed with a piece of sterile tape. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. This procedure involves numbing a small region of skin near the belly button with a local anesthetic, using a needle a small amount of fat tissue is removed from underneath the skin. During the procedure subjects will feel some pinching and pulling, but it should not be very painful. The injury resulting from the muscle and fat tissue biopsies is rather minor. Subjects will likely have some bruising and mild soreness, but it should not prevent them from performing their general daily activities. Approximately 2.5 hours after admission, the study team will begin the tracer-labeled fat infusion. The tracer-labeled fats the study team are infusing occur naturally in the body. By injecting a slightly greater amount of this substance than what is already in the body the study team will be able to measure the rate of fat breakdown and fat burning. After about 50 minutes of the infusion, three blood samples will be obtained in 5 min intervals. After, the study team will begin a hyperinsulinemic-euglycemic clamp procedure (a procedure to measure the body's sensitivity to insulin). During this procedure the study team will infuse insulin and glucose through the IV and will collect blood samples every 5 minutes for the duration of the procedure to monitor the subjects blood glucose and blood insulin concentrations. This procedure is designed to last 2 hours. The study team will change the infusion rate of glucose accordingly to ensure that the subjects blood sugar is maintained at a healthy/normal level. The study team will also infuse a small amount of potassium to make sure potassium concentrations remain at healthy/normal levels. About 30 minutes after starting this procedure to measure the body's sensitivity to insulin, the study team will collect another sample of muscle from the thigh and fat tissue from the area just underneath the skin near the belly button. After completing the hyperinsulinemic-euglycemic clamp procedure, subjects will be provided a meal, and the study team will continue to monitor the subjects blood glucose concentration until stable. When the subjects vital signs are stable, the study team will also measure percent body fat using a Dual Energy X-ray Absorptiometry (DEXA) and intra-abdominal fat by Magnetic resonance imaging (MRI). When the DEXA scan and MRI tests have been completed, subjects will be discharged from the hospital. Depending on scheduling, however, the DEXA scan and MRI tests may be performed on a separate occasion from the study trial admission.

Interventions

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index \[BMI\]: 30-40 kg/m2 * Age: 18-45 years * All women must be pre-menopausal * Non-exerciser: no regularly planned exercise/physical activity

Exclusion criteria

* Weight instability ≥ ±3kg ≥ 6 months * Medications known to affect lipid and/or glucose metabolism * Pregnancy or actively breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Insulin Sensitivitybaseline (this cross-sectional study involves only one insulin sensitivity measurement in a single visit for each participant)A hyperinsulinemic-euglycemic clamp will be used to assess peripheral insulin sensitivity

Secondary

MeasureTime frameDescription
Resting Metabolic Ratebaseline (this cross-sectional study involves only one Resting Metabolic Rate measurement in a single visit for each participant)Resting metabolic rate was measured using a metabolic cart (to measure VO2 and VCO2) in the morning after an overnight fast

Countries

United States

Participant flow

Participants by arm

ArmCount
Insulin Sensitivity
hyperinsulinemic-euglycemic clamp
20
Total20

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyInability to place IV3

Baseline characteristics

CharacteristicInsulin Sensitivity
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
13 Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Insulin Sensitivity

A hyperinsulinemic-euglycemic clamp will be used to assess peripheral insulin sensitivity

Time frame: baseline (this cross-sectional study involves only one insulin sensitivity measurement in a single visit for each participant)

Population: BMI: 30-40 kg/m2; waist circumference: 88-98cm for women and 100-110cm for men), age: 18-45 years old), weight stable (±3kg for ≥ 6 months), No medications known to affect lipid or glucose metabolism. No evidence and/or history of cardiovascular or metabolic diseases All women were pre-menopausal with regularly occurring menses.

ArmMeasureValue (MEAN)Dispersion
Low Insulin Sensitivity GroupInsulin Sensitivity273 nmol/kg FFM/min /(µU/mL Insulin)Standard Deviation 54
High Insulin Sensitivity GroupInsulin Sensitivity817 nmol/kg FFM/min /(µU/mL Insulin)Standard Deviation 257
Secondary

Resting Metabolic Rate

Resting metabolic rate was measured using a metabolic cart (to measure VO2 and VCO2) in the morning after an overnight fast

Time frame: baseline (this cross-sectional study involves only one Resting Metabolic Rate measurement in a single visit for each participant)

Population: BMI: 30-40 kg/m2; waist circumference: 88-98cm for women and 100-110cm for men), age: 18-45 years old), weight stable (±3kg for ≥ 6 months), No medications known to affect lipid or glucose metabolism. No evidence and/or history of cardiovascular or metabolic diseases All women were pre-menopausal with regularly occurring menses.

ArmMeasureValue (MEAN)Dispersion
Low Insulin Sensitivity GroupResting Metabolic Rate1509 kcals/dayStandard Deviation 237
High Insulin Sensitivity GroupResting Metabolic Rate1325 kcals/dayStandard Deviation 198

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026